Skip to main content
. 2022 Dec 2;83(6):694–701. doi: 10.1055/a-1963-7511

Fig. 1.

Fig. 1

Univariate analysis of pathological complete response (pCR) rates after neoadjuvant therapy (NAT) in patients treated with ABP 980 versus reference trastuzumab (RTZ). Error bars represent 95% confidence intervals. p = 0.829 (chi-squared-test).